MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from december
2025 public offering...
$55,424,354
Proceeds from may 2025
public offering of...
$4,214,506
Issuance of common stock
from the exercise of...
$2,249,000
Proceeds from issuance of
common stock under atm...
$2,078,348
Proceeds from the sale of
equipment
$11,000
Proceeds from issuance of
common stock from the...
$871
Net cash provided by
financing activities
$63,518,800
Effect of foreign
currency translation on...
$18,766
Net cash provided by
investing activities
$11,000
Canceled cashflow
$448,279
Net change in cash,
cash equivalents,...
$48,337,076
Canceled cashflow
$15,211,490
Payments on financed
director and officer...
$448,279
Impairment expense
$4,162,911
Amortization expense
$630,164
Change in fair value of
derivative warrant...
$416,619
Stock-based compensation
$297,467
Loss on asset
disposal
$103,322
Depreciation
$32,421
Accounts payable and
accrued liabilities
$11,233
Realized foreign
currency translation...
-$7,171
Net cash used in
operating activities
-$15,211,490
Canceled cashflow
$5,661,308
Net loss
-$20,427,683
Other current assets
$269,278
Change in fair value of
warrant liabilities
-$115,301
Prepaid expenses
$60,536
Back
Back
Cash Flow
source: myfinsight.com
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)